Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Maintains $1135 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has maintained a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a price target of $1135.

March 26, 2024 | 1:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities maintains a Buy rating on Regeneron Pharmaceuticals with a $1135 price target.
The maintenance of a Buy rating and a high price target by a reputable analyst like Robyn Karnauskas from Truist Securities suggests a strong confidence in Regeneron Pharmaceuticals' future performance. This endorsement is likely to instill positive sentiment among investors, potentially leading to a short-term uptick in REGN's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100